| Titre : | Association between baseline factors and linezolid dose reduction in a non-linezolid randomized sample from the endTB clinical trial |
| Auteurs : | Leydi Moran ; Ecole des hautes études en santé publique (EHESP) (Rennes, FRA) |
| Type de document : | Mémoire |
| Année de publication : | 2024 |
| Description : | 41p. / fig., tabl |
| Langues: | Anglais |
| Classement : | MPH/ (Mémoires MPH à partir de 2024) |
| Mots-clés : | Essai thérapeutique ; Infection ; Tuberculose pulmonaire ; Bactérie ; Pharmacorésistance ; Thérapeutique ; Médicament antibiotique ; Géorgie ; Lesotho ; Pérou ; Afrique du Sud |
| Résumé : | Background: Tuberculosis is the second leading cause of death in infectious diseases. Treatment has become a priority in the fight against the disease, particularly MDR-TB. Linezolid was approved for use as part of MDR-TB treatment, but its dosing is still under investigation to balance efficacy and toxicity.Methods: This cross-sectional study used a sample of non-linezolid randomized MDR-TB participants from the linezolid-containing arms of the endTB clinical trial (NCT02754765). All participants received initially 600 mg of linezolid daily and were subsequently reduced to either 300 mg daily or 600 mg thrice weekly by the clinician's decision. The aim of this study was to assess the association between participant’s baseline characteristics and linezolid dose reduction strategy.Results: From 193 non-linezolid-randomized participants, 85 were assigned to 300 mg daily and 108 to 600 mg thrice weekly. Investigators from trials countries such as Georgia, Lesotho, Peru, and South Africa allocated most or all the participants in one single linezolid dose reduction strategy. However, using a multivariable relative risk regression, sex, smoking, HIV status and performance status were found significantly associated with the linezolid dose reduction srategy. Males (aRR = 1.31, 95% CI = 1.01, 1.69) and participants with reduced performance status (aRR=1.44, 95% CI= 1.07, 1.92) had higher risk to being assigned to 600 mg thrice weekly. While people living with HIV (aRR= 0.17, 95% CI= 0.06, 0.50) and smokers (aRR=0.74, 95% CI = 0.57, 0.97) had a lower risk to being assigned to 600 mg thrice weekly.Conclusions: Country was found to explain most of the variability associated with linezolid dose reduction strategies (300 mg daily and 600 mg thrice weekly). Other baseline variables were found to be associated, although it is difficult to establish their precise role. |
| Diplôme : | Master MPH of public health |
| Plan de classement simplifié : | Master of Public Health - master international de Santé Publique (MPH) |
| En ligne : | https://documentation.ehesp.fr/memoires/2024/mph/leydi_moran.pdf |
Documents numériques (1)
 FullText URL |